VRNA Dec 2024 22.500 put
| Previous close | 8.80 |
| Open | 8.50 |
| Bid | 8.20 |
| Ask | 8.80 |
| Strike | 22.50 |
| Expiry date | 2024-12-20 |
| Day's range | 8.50 - 8.80 |
| Contract range | N/A |
| Volume | |
| Open interest | 28 |
BenzingaFirst Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product
On Wednesday, the FDA approved Verona Pharma plc’s (NASDAQ:VRNA) Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. Ohtuvayre is the first inhaled product with a novel mechanism of action available for the maintenance treatment of COPD in more than 20 years. Related: Verona Pharma’s Promising COPD Treatment Puts It in GSK’s Acquisition Crosshairs, Analysts Predict Big Moves. Ohtuvayre is a first-in-class selective dual inhibi
GlobeNewswireVerona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)
Ohtuvayre is indicated for the maintenance treatment of COPD allowing for broad use in COPD patients First inhaled COPD treatment providing bronchodilation and non-steroidal anti-inflammatory effects Conference call tomorrow at 8:30 a.m. EDT / 1:30 p.m. BST LONDON and RALEIGH, N.C., June 26, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces the US Food and Drug Administration (“FDA”) approved Ohtuvayre (ensifentrine) for the maintenance treat
Investor's Business DailyWhy It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks
There hasn't been a new COPD treatment in years. But Regeneron stock analysts are closely watching a pair of key FDA decisions.
